This website is intended for healthcare professionals

PREVIEW: 12th Clinical Trials in CNS

Posted in on 22nd Sep 2013

Conference details: 18 & 19 November 2013, London, UK.

With an ever increasing average life expectancy neurodegenerative diseases are increasingly becoming more prevalent in society; this results in an increased need for new and improved therapies for treating these neurodegenerative conditions. From Alzheimers to Parkinsons disease the target and mechanism by which a disease manifests is unique and presents challenges in how to approach such treatments not to mention ethical and legal issues behind treatment and trial design.

Clinical Trials in CNS is a two day content packed agenda featuring new approaches taken in this field towards a number of neurodegenerative disorders, from clinical trial modelling and simulation to the role of biomarkers.  The agenda presents a detailed look into many aspects of drug discovery and delivery of CNS therapeutics. This innovative conference will give delegates an opportunity to gain insights through case studies and interactive discussion into the best practices to design late stage clinical trials, the importance of understanding the pathophysiology and biology of disease processes with use of biomarkers and imaging techniques. The event also provides an overview of how to overcome challenges of delivery within the CNS.

Keynote Speakers

SMi are pleased to introduce Johannes Streffer, Director of Experimental Medicine Europe, Neurologist, Johnson & Johnson, who will give a presentation on Translational Medicine Models in Neurodegenerative diseases looking at continuous CSF measurements: Indwelling CSF catheters for monitoring CNS effects.

The conference will also feature presentation on early detection of Alzheimer’s Disease in Mid-life lead by Craig Ritchie, Clinical Senior Lecturer, Imperial College London, highlighting pathological changes in mid-life which lead to dementia in older people and outline UK-based infrastructure initiatives to support translational medicine innovations in dementia research around mid-life and early dementia.

Visit for the full speaker line-up, which includes presentations from: NIH/NINDS, Janssen Scientific Affairs, LLC; The Cure Parkinsons Trust, UCB Pharma, Eli Lilly and many more.

Attendees can also attend a half day workshop held on 20th November which will be on: Defining Clinical Relevance. Led by QCTR, the workshop will examine how to develop a better awareness of the limitations of primary outcome measures in neurological diseases and how to select and make a case to regulatory authorities for a single efficacy outcome measure.

Visit for more information or Contact Jonathan Collins on +44 (0)20 7827 6734 or email:

** Quote SMI2G5N during checkout to receive £300 discount **

ACNR 2013;13:5:34